posted on 2004-07-01, 00:00authored byMarit Kristiansen, Birgitte Andersen, Lars Fogh Iversen, Niels Westergaard
Inhibition of glycogen phosphorylase (GP) has attracted considerable attention during the last
five to 10 years as a means of treating the elevated hepatic glucose production seen in patients
with type 2 diabetes. Several different GP inhibitors binding to various binding sites of the
GP enzyme have been reported in the literature. In this paper we report on a novel class of
compounds that have been identified as potent GP inhibitors. Their synthesis, mode of binding
to the allosteric AMP site as well as in vitro data on GP inhibition are shown. The most potent
inhibitor was found to be 4-[2,4-bis-(3-nitrobenzoylamino)phenoxy]phthalic acid (4j) with an
IC50 value of 74 nM. This compound together with a closely related analogue was further
characterized by enzyme kinetics and in primary rat hepatocytes.